Change over period: —
NSE · FDC
FDC LIMITED
-13.9% from the 52-week high · +16.4% above the low
FDC Ltd. engages in the business of pharmaceutical. The company is headquartered in Mumbai, Maharashtra. The firm manufactures and distributes its range of generics, formulations and active pharmaceuticals at its manufacturing plants. The company also manufactures oral rehydration salts (ORS) and specialized formulations. The company has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. The company has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
The short version. FDC LIMITED reported revenue of ₹572 crore for Sep 2026, up 20.9% from a year earlier. Net profit was ₹50 crore (up 78.6% year on year). Return on equity was 11.3% in Mar 2026. Promoter holding was 69.66% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
FDC LIMITED trades 13.9% below its 52-week high and 16.4% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹572 cr.
Sep 2026 net profit of ₹50 cr.
2.7 pts higher than a year earlier.
Revenue compounded at 7.6% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 572 | 668 | 585 | 465 | 473 | 648 | 492 | 464 |
| Net profit | 50 | 132 | 103 | 28 | 28 | 121 | 39 | 37 |
| Net margin % | 8.7 | 19.8 | 17.7 | 6.1 | 6.0 | 18.7 | 7.9 | 8.1 |
| EPS (₹) | 3.07 | 8.14 | 6.35 | 1.74 | 1.74 | 7.45 | 2.38 | 2.3 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2171 | 2108 | 1943 | 1784 | 1528 | 1333 | 1344 | 1083 |
| Net profit | 281 | 267 | 305 | 194 | 216 | 301 | 240 | 174 |
| Net margin % | 13.0 | 12.7 | 15.7 | 10.9 | 14.1 | 22.6 | 17.8 | 16.0 |
| EPS (₹) | 17.29 | 16.39 | 18.75 | 11.7 | 12.81 | 17.85 | 14.03 | 9.95 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 11.3% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 11.3 | 11.7 | 14.5 | 9.8 |
| Return on capital % | 14.9 | 15.4 | 18.6 | 12.9 |
| EBITDA margin % | 19.2 | 18.9 | 21.5 | 16.4 |
| Net margin % | 12.3 | 12.1 | 14.9 | 10.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 7.6% | 9.8% |
| Profit CAGR | 13.2% | -1.4% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Down 1.09 pts over 8 quarters.
Up 0.51 pts over 8 quarters.
+2 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.66 | 69.66 | 69.66 | 69.66 | 69.66 | 69.66 | 69.66 | 69.66 | 0.0 |
| FII | 2.67 | 2.55 | 2.41 | 2.43 | 2.32 | 2.4 | 1.4 | 1.58 | -1.09 |
| DII | 6.08 | 6.37 | 7.17 | 6.82 | 6.27 | 6.29 | 6.31 | 6.59 | +0.51 |
| Public | 21.59 | 21.42 | 20.76 | 21.1 | 21.75 | 21.65 | 22.63 | 22.17 | +0.58 |
Mutual fund holdings · Oct 2026
14 schemes hold this stock
12 the month before.
- TATA INDIA PHARMA & HEALTHCARE FUND2.69% of NAV
- ICICI Prudential ESG Exclusionary Strategy Fund1.62% of NAV
- ICICI Prudential MNC Fund1.12% of NAV
- ICICI Prudential Retirement Fund - Pure Equity Plan1.07% of NAV
- ICICI Prudential Healthcare Fund0.71% of NAV
- ICICI Prudential Small Cap Fund0.59% of NAV
- NIPPON INDIA SMALL CAP FUND0.21% of NAV
- ICICI Prudential Bharat Consumption Fund0.14% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for FDC LIMITED are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about FDC LIMITED
What is the FDC LIMITED share price?
FDC LIMITED (FDC) last closed at ₹378.05, up 1.11% on the day. Its 52-week range is ₹321.10 to ₹434.25.
What is the market cap of FDC LIMITED?
FDC LIMITED has a market capitalisation of about ₹6,087 crore. Its price-to-earnings ratio is 19.6.
How are FDC LIMITED's latest results?
FDC LIMITED reported revenue of ₹572 crore for Sep 2026, up 20.9% from a year earlier. Net profit was ₹50 crore (up 78.6% year on year). Return on equity was 11.3% in Mar 2026. Promoter holding was 69.66% in Sep 2026, up 0.00 points over 8 quarters.
Who owns FDC LIMITED?
As of Sep 2026, shareholding was: Promoter 69.66%, FII 1.58%, DII 6.59%, Public 22.17%.
How many mutual funds hold FDC LIMITED?
14 mutual fund schemes held FDC LIMITED in October 2026. That compares with 12 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 11 Feb 2026 · Interim Dividend - Rs. 5
- 22 Nov 2024 · Interim Dividend - Rs. 5
- 19 Mar 2020 · Interim Dividend - Rs. 0.8
- 08 Aug 2017 · Dividend - Rs. 2.25
- 17 Mar 2016 · Interim Dividend - Rs. 2.25
- 23 Sep 2015 · Final Dividend - Rs. 2.25
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.